中国循证医学杂志
中國循證醫學雜誌
중국순증의학잡지
CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE
2010年
2期
132-139
,共8页
袁强%王莉%成岚%崔小花%钟大可%李媛媛%商洪才%张伯礼%李幼平
袁彊%王莉%成嵐%崔小花%鐘大可%李媛媛%商洪纔%張伯禮%李幼平
원강%왕리%성람%최소화%종대가%리원원%상홍재%장백례%리유평
中药注射剂%基本药物%药物不良反应%不良事件
中藥註射劑%基本藥物%藥物不良反應%不良事件
중약주사제%기본약물%약물불량반응%불량사건
Chinese medicine injections%Essential medicine%Adverse drug reaction%Adverse event
目的 了解国家基本药物目录(2004年版)33种中药注射剂不良反应/不良事件(ADR/AE)的基本情况和文献研究趋势,为中药注射剂研发、合理使用与安全警戒,以及风险管理工作提供参考依据.方法 电子检索中国生物医学文献数据库(1978.1~2009.4)、中国期刊全文数据库(1979.1~2009.4)、中文科技期刊数据库(1989.1~2009.4)、中国中医药数据库(1984.1~2009.4).同时检索卫生部及国家食品药品监督管理局(SFDA)网站,收集<药品不良反应信息通报>第1~22期中药注射剂ADR/AE相关信息.描述性分析我国中药注射剂ADR研究文献的发表时间、期刊和文献类型及出现ADR的中药注射剂和相应管理措施.结果 ①上述4个数据库共检出5 405篇文献,剔除重复文献2 160篇后,再按纳入与排除标准筛查文题、摘要和全文,最终纳入1 010篇.②自1991年起,中药注射剂ADR年文献发表总量和年文献累积量均明显递增.③纳入的1 010篇文献分布在297种期刊,其中55种药学类期刊共发表399篇(占文献总量的39.50%),64种中医、药类期刊共发表197篇(占19.50%),<中文核心期刊要目总览(2008年版)>医药卫生类收录的22种期刊共发表129篇(占12.77%).④该1 010篇文献分属8种类型,包括348篇个案报告(34.46%),254篇系列病例(25.15%),119篇综述(11.78%),116篇RCT(11.49%),78篇横断面研究(7.72%),61篇ADR文献分析(6.04%),28篇非随机对照试验(2.77%).⑤<药物不良反应杂志><医药导报>和<中国药业>ADR文献发表量居297种期刊前三位(分别占5.84%、3.76%和2.67%).⑥双黄连、清开灵和鱼腥草ADR报道最多,均超过200篇文献,占总文献的41.95%,国家卫生部和SFDA分别对其ADR进行管制.⑦双黄连、刺五加、鱼腥草和菌栀黄4种中药注射剂分别被撤市或叫停,其ADR文献发表量与监管作用相辅相成.结论 ①中药注射剂ADR研究呈增长态势,但总的数量少、发表分散、质量不高;②迫切需要研究制定中药注射剂ADR的分级和风险评价标准;③应有组织地推动中药注射剂安全性再评价和合理用药的宣传普及.
目的 瞭解國傢基本藥物目錄(2004年版)33種中藥註射劑不良反應/不良事件(ADR/AE)的基本情況和文獻研究趨勢,為中藥註射劑研髮、閤理使用與安全警戒,以及風險管理工作提供參攷依據.方法 電子檢索中國生物醫學文獻數據庫(1978.1~2009.4)、中國期刊全文數據庫(1979.1~2009.4)、中文科技期刊數據庫(1989.1~2009.4)、中國中醫藥數據庫(1984.1~2009.4).同時檢索衛生部及國傢食品藥品鑑督管理跼(SFDA)網站,收集<藥品不良反應信息通報>第1~22期中藥註射劑ADR/AE相關信息.描述性分析我國中藥註射劑ADR研究文獻的髮錶時間、期刊和文獻類型及齣現ADR的中藥註射劑和相應管理措施.結果 ①上述4箇數據庫共檢齣5 405篇文獻,剔除重複文獻2 160篇後,再按納入與排除標準篩查文題、摘要和全文,最終納入1 010篇.②自1991年起,中藥註射劑ADR年文獻髮錶總量和年文獻纍積量均明顯遞增.③納入的1 010篇文獻分佈在297種期刊,其中55種藥學類期刊共髮錶399篇(佔文獻總量的39.50%),64種中醫、藥類期刊共髮錶197篇(佔19.50%),<中文覈心期刊要目總覽(2008年版)>醫藥衛生類收錄的22種期刊共髮錶129篇(佔12.77%).④該1 010篇文獻分屬8種類型,包括348篇箇案報告(34.46%),254篇繫列病例(25.15%),119篇綜述(11.78%),116篇RCT(11.49%),78篇橫斷麵研究(7.72%),61篇ADR文獻分析(6.04%),28篇非隨機對照試驗(2.77%).⑤<藥物不良反應雜誌><醫藥導報>和<中國藥業>ADR文獻髮錶量居297種期刊前三位(分彆佔5.84%、3.76%和2.67%).⑥雙黃連、清開靈和魚腥草ADR報道最多,均超過200篇文獻,佔總文獻的41.95%,國傢衛生部和SFDA分彆對其ADR進行管製.⑦雙黃連、刺五加、魚腥草和菌梔黃4種中藥註射劑分彆被撤市或叫停,其ADR文獻髮錶量與鑑管作用相輔相成.結論 ①中藥註射劑ADR研究呈增長態勢,但總的數量少、髮錶分散、質量不高;②迫切需要研究製定中藥註射劑ADR的分級和風險評價標準;③應有組織地推動中藥註射劑安全性再評價和閤理用藥的宣傳普及.
목적 료해국가기본약물목록(2004년판)33충중약주사제불량반응/불량사건(ADR/AE)적기본정황화문헌연구추세,위중약주사제연발、합리사용여안전경계,이급풍험관리공작제공삼고의거.방법 전자검색중국생물의학문헌수거고(1978.1~2009.4)、중국기간전문수거고(1979.1~2009.4)、중문과기기간수거고(1989.1~2009.4)、중국중의약수거고(1984.1~2009.4).동시검색위생부급국가식품약품감독관리국(SFDA)망참,수집<약품불량반응신식통보>제1~22기중약주사제ADR/AE상관신식.묘술성분석아국중약주사제ADR연구문헌적발표시간、기간화문헌류형급출현ADR적중약주사제화상응관리조시.결과 ①상술4개수거고공검출5 405편문헌,척제중복문헌2 160편후,재안납입여배제표준사사문제、적요화전문,최종납입1 010편.②자1991년기,중약주사제ADR년문헌발표총량화년문헌루적량균명현체증.③납입적1 010편문헌분포재297충기간,기중55충약학류기간공발표399편(점문헌총량적39.50%),64충중의、약류기간공발표197편(점19.50%),<중문핵심기간요목총람(2008년판)>의약위생류수록적22충기간공발표129편(점12.77%).④해1 010편문헌분속8충류형,포괄348편개안보고(34.46%),254편계렬병례(25.15%),119편종술(11.78%),116편RCT(11.49%),78편횡단면연구(7.72%),61편ADR문헌분석(6.04%),28편비수궤대조시험(2.77%).⑤<약물불량반응잡지><의약도보>화<중국약업>ADR문헌발표량거297충기간전삼위(분별점5.84%、3.76%화2.67%).⑥쌍황련、청개령화어성초ADR보도최다,균초과200편문헌,점총문헌적41.95%,국가위생부화SFDA분별대기ADR진행관제.⑦쌍황련、자오가、어성초화균치황4충중약주사제분별피철시혹규정,기ADR문헌발표량여감관작용상보상성.결론 ①중약주사제ADR연구정증장태세,단총적수량소、발표분산、질량불고;②박절수요연구제정중약주사제ADR적분급화풍험평개표준;③응유조직지추동중약주사제안전성재평개화합리용약적선전보급.
Objectives We conducted a literature review of 33 kinds of Traditional Chinese medicine injections (CMIs)on the national essential medicine list(2004 edition)of China in ADR articles to retrieve basic ADR information and research trends related to CMIs and to provide evidence for the research and development as well as the rational use of CMIs,particularly pharmacovigilance and risk management of CMIs.Methods We electronically searched Chinese Biomedical Literature Database(CBM,Jan.1978-April 2009),the China National Knowledge Infrastructure Database (CNKI,Jan.1979-April 2009),Chinese Science and Technology Periodical Database(VIP,Jan.1989-April 2009)and the Traditional Chinese Medicine Database(Jan.1984 April 2009).We also retrieved the websites of Ministry of Health and State Food and Drug Administration,to collect data about CMIs ADRs reports and regulations from "Newsletter of Adverse Drug Reactions"(Issue 1 to 22).Then we descriptively analyzed all the results on the year published,periodicals and types of study design of included ADR literatures,the major CMIs as well as the regulations about their ADRs.Results(1)There were 5 405 citations found in total and 2160 were removed became of duplication.After screening the title,abstract and full text of the selected papers,1 010 studies finally met the eligible criteria.(2)The total and cumulative amount of research articles published about CMIs ADRs significantly increases over time.(3)The included 1,010 articles were scattered among 297 periodicals.A total of 55 journals on pharmaceutical medicine,containing 399 articles,accounted for 39.50% of total;64 journals on traditional Chinese medicine and pharmaceutical medicine,containing only 197 articles,amounted for 19.50% of total.Only 22 periodicals were included on the core journals of the Beijing University List(2008 edition)(8.94% of the total journals in the list),which published 129 articles(12.77% of the total articles published).(4)We categorized the articles included into eight categories based on their content and study methodology.There were:348 case reports and 254 case series which accounted for 34.46% and 25.15% of the total articles,119 overviews(11.78%),116 randomized controlled trials(11.49%),78 cross-sectional studies(7.72%),61 ADR literature analyses(6.04%),and 28 non-randomized controlled clinical studies(2.77%).(5)In the three of top ten journals,"Adverse Drug Reactions Journal,""China Medical Herald",and "Chinese Pharmaceuticals" published literature accounted for 5.84%,3.76% and 2.67% of the total respectively.(6)The reports of ADRs to Shuanghuanglian,Qingkailing and Yuxingcao injections were the most in all reports for CMIs(All the three injections had more than 200 articles,accounting for 41.95% of the total).The Ministry of Health and the State Food and Drug Administration took measures to supervise them.(7)The four kinds of CMIs(Shuanghuanglian,Ciwujia,Yuxingcao,and Yinzhihuang injections)among the top 5 reported ADR literatures were removed from the market or were suspended for sale.The varieties and numbers of reports for CMIs ADRs have relationship with the supervision to them.Conclusions(1)Articles published on CMIs ADRs increased year by year,but overall the research is of low quality and is scattered in a large number of sources.(2)It is very urgent to create a clear standard to grade ADRs of CMIs for the risk management.(3)It is necessary to enforce safety re-evaluation work for CMIs and to promote the clinical rational use.